Remote Monitoring To Identify Worsening Heart Failure The REMOTI-HF Randomized Clinical Trial

Launched by CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA, E.P.E. · May 15, 2024

Keywords

ClinConnect Summary

The REMOTI-HF clinical trial is studying how remote monitoring can help manage heart failure in patients who have specific heart devices, like an implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy (CRT). The goal is to see if using technology to track patients’ health can reduce the number of hospital visits and improve overall survival rates. Researchers will also look at how physical activity impacts heart health and compare the data from monitoring devices with a blood test marker called NT-proBNP, which helps assess heart failure.

To participate in this study, you need to be between 65 and 85 years old, have one of the heart devices mentioned, and have a heart condition where your heart doesn’t pump blood very well (with a measurement called left ventricular ejection fraction of 35% or less). Unfortunately, people under 18, those who cannot be reached when they are not in the hospital, or those with severe cognitive impairment cannot join. If eligible, participants can expect to be monitored remotely, which means they will use technology to track their health from home. This trial aims to improve care for heart failure patients by exploring new ways to manage their condition effectively.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Possession of an implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy (CRT) device that is compatible with the HeartLogic or TriageHF algorithms.
• • Left ventricular ejection fraction at the time of device implantation must be equal to or less than 35%.
• Exclusion Criteria:
• • Younger than 18 years old or older than 85 years old.
• • Unable to be contacted when out of the hospital.
• • Presence of severe cognitive impairment.
• • Currently on the heart transplant waiting list